-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Dr. Reddys Laboratories Limited July 30, 2014
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Business Highlights
2
Revenues Gross Profit
R & D EBITDA
YoY Gr
24% 2,845 3,518 52.8% 59.3%
39% 1,502 2,084
8.5% 11%
59% 243 388
20.0% 25.2%
56% 569 888
Q1FY14 Q1FY15
YoY Gr
YoY Gr YoY Gr
All values are in rupees crores ;encapsulated figures are % to
revenues
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Launches & filings
US 4
Europe 3
RoW 4
Country wise launches
Russia & CIS 5
India 9
9
5
3
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Global Generics: 2,900 Cr (32% YoYGr)
4
US
1,647 Cr (51%)
Emerging Markets
708 Cr (19%)
India
400 Cr (15%)
Europe
146 Cr (-7%)
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Global Generics: US
Market Share Key Products
ANDA Pipeline
Cr Revenues
218 Cumulative
ANDAs
70 Pending final approvals
42 Para IVs 8 First-to-Files
(FTFs)
Product March May
Decitabine 58% 66%
Azacitidine 44% 44%
Zoledronic acid (5mg/100ml)
60% 62%
Ziprasidone 20% 38%
Metoprolol 16% 17%
Divalproex ER 9% 11%
Source: IMS total market share
Q1 FY 14 Q1 FY 15
1,087 1,647
51%
5
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
6
Global Generics: Emerging markets
Cr Revenues RUSSIA
IMS YTD May: Growth faster than the market, both in unit and
value terms: Improved by 1 rank, from 17th to 16th
IMS OTC YTD May: 3rd fastest growing OTC company in Top 25
(volume wise) with a growth rate of 24% against a market growth of
1.5%
OTC revenues grew 22.3% YoY
RoW
Venezuela: Revenues grew by 107% YoY in constant currency (76%
unit growth against market growth of 7%)
19% 597
708
Q1 FY 14 Q1 FY 15
365 420
83 66
149 222
Russia CIS RoW
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
7
Global Generics: India
Cr Revenues Second successive quarter of
encouraging above industry growth
Healthy volume expansion in our focus brands
IMS MAT June 2014 growth of 9.6% vs IPM growth of 9.4%
9 new products launched in the quarter Q1 FY 14 Q1 FY 15
349 400
15%
Key Product launches
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
8
PSAI
API: Stability in revenue with better margin profile and higher
developmental sales
CPS: Performance fell short of expectations due to deferment of
customer orders
5 US DMF filings during the quarter
Cr
Q1 FY 14 Q1 FY 15
587 554 DMFs Pipeline
US 213
Europe 180
RoW 285
Cumulative 678
Revenues
-6%
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
9
CAPEX, R&D & Free cash-flows
Net Debt/Equity ratio
(June 2014)
591 767
1,240
388
FY 12 FY 13 FY 14 Q1 FY15
R&D
686 667
1,020
217
FY 12 FY 13 FY 14 Q1 FY15
CAPEX
695 589
873
227
FY 12 FY 13 FY 14 Q1 FY15
Free cash flow
Cr Cr
Cr
0.09
7%
9%
6%
11%
% of revenues
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
Q&A Session
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
11
P&L Q1 FY 15 Cr
Particulars Q1 FY15 Q1 FY14 Gr%
Revenues 3,518 2,845 24%
Gross Profit 2,084 1,502 39%
% to revenues 59.3% 52.8%
SG&A 1,068 879 21%
% to revenues 30.4% 30.9%
R&D 388 243 59%
% to revenues 11.0% 8.5%
EBITDA 888 569 56%
% to revenues 25.2% 20.0%
PAT 550 361 52%
% to revenues 15.6% 12.7%
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
12
Key Balance Sheet Items
Cr
Particulars Jun14 Mar14
Cash, cash equivalents & other investments 3,295 3,353
Trade & other receivables 3,611 3,304
Inventories 2,532 2,399
Property, plant & equipment 4,535 4,442
Loans & borrowings (current & non current) 4,182
4,474
Trade & other payables 1,064 1,050
Equity 9,673 9,080
-
2014 Dr. Reddy's Laboratories Limited. All Rights Reserved.
Q1 FY15 PRESS MEET
THANK YOU
